Diagnostic Imaging Drug Development Expertise
From lab to market
We provide full-service Imaging Diagnostics Clinical Development, from pre-clinical to IND and NDA submission and Medical Affairs.
We have developed current market leaders
We have led 7 imaging new drug approvals globally: MRI, CT, and radiopharmaceuticals.
Literature-based approvals
Utilizing only existing literature reviews, we have gained 5 new indications for imaging drugs without performing additional clinical trials.
Over 40 years of experience
Between our two RadMD principals, there are over 40 years of contrast agent development experience.
Imaging management solutions
Our full-service imaging management solutions provide a comprehensive set of services to support pharmaceutical, medical device, and AI companies with their clinical trials.
Our reader group
We are the global leader in providing consultants to perform imaging BICR (blinded independent central reviews)
Diagnostic Imaging Drug Development Expertise
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
We have 12 years of experience in comprehensive sourcing and management of our readers for over 600 trials.
Latest News
Medica Group finance leadership summit 2024
Last week, the annual Medica Group finance leadership summit was held at Medica Ireland's Carrickmines clinic, bringing together team members from Medica UK, Ireland and RadMD. The event provided a…
RadMD hosts it’s first webinar of 2024: Performing Live Blinded Central Reads in Cancer Trials
Rick Patt, MD, Co-Founder, and Principal of RadMD, led the first webinar of 2024, highlighting live blinded central reads (BICR) in cancer trials. Here are the key points that were covered:…
RadMD’s Juan Gutierrez MD Leads the Way in Imaging Core Lab Selection at OCT West Coast
Dr. Juan Gutierrez, Medical Director at RadMD, brought his extensive expertise to the forefront at the OCT West Coast conference on February 13. His presentation, "Selecting an Imaging…